Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Net Asset Quality Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Net Asset Quality Index of 95.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.40 Billion minus total liabilities of CN¥117.63 Million yields net assets of CN¥2.28 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 301211 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Net Asset Quality Index Over Time (2017–2025)
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Net Asset Quality Index has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the index stands at 95.1%, representing net assets of CN¥2.28 Billion against total assets of CN¥2.40 Billion CNY. See 301211 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below presents the year-by-year Net Asset Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hubei Biocause Heilen Pharmaceutical Co. market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | CN¥2.27 Billion | CN¥2.40 Billion | CN¥128.65 Million | ▲ +1.8 pp |
| 2024 | 92.8% | CN¥2.31 Billion | CN¥2.49 Billion | CN¥178.97 Million | ▲ +0.3 pp |
| 2023 | 92.5% | CN¥2.36 Billion | CN¥2.55 Billion | CN¥189.89 Million | ▲ +1.4 pp |
| 2022 | 91.1% | CN¥2.28 Billion | CN¥2.50 Billion | CN¥221.22 Million | ▼ -4.2 pp |
| 2021 | 95.4% | CN¥2.22 Billion | CN¥2.33 Billion | CN¥107.53 Million | ▲ +8.2 pp |
| 2020 | 87.2% | CN¥700.39 Million | CN¥803.25 Million | CN¥102.85 Million | ▲ +21.7 pp |
| 2019 | 65.5% | CN¥488.25 Million | CN¥745.56 Million | CN¥257.31 Million | ▲ +3.0 pp |
| 2018 | 62.5% | CN¥399.87 Million | CN¥640.24 Million | CN¥240.36 Million | ▲ +4.9 pp |
| 2017 | 57.5% | CN¥307.65 Million | CN¥534.90 Million | CN¥227.25 Million | — |